8C4 Stock Overview Researches, develops, produces, sell, leases, and maintains robotic equipment and systems for medical and welfare in Japan, the United States, Europe, the Middle East, Africa, and the Asia Pacific countries. More details
Rewards Risk Analysis No risks detected for 8C4 from our risk checks.
See All Risk Checks Capture your thoughts, links and company narrative
CYBERDYNE Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for CYBERDYNE Historical stock prices Current Share Price JP¥0.94 52 Week High JP¥1.57 52 Week Low JP¥0.94 Beta 0.46 1 Month Change -16.34% 3 Month Change -21.24% 1 Year Change -28.09% 3 Year Change -63.77% 5 Year Change -80.04% Change since IPO -84.62%
Recent News & Updates
CYBERDYNE Inc. Announces on the New Product Medical Vital Sensor Cyvis M100 Dec 10
CYBERDYNE Inc. to Report First Half, 2025 Results on Nov 14, 2024 Sep 20
First quarter 2025 earnings released: EPS: JP¥0.052 (vs JP¥1.56 in 1Q 2024) Aug 19
Now 21% overvalued after recent price rise Jul 12
Full year 2024 earnings released: JP¥6.99 loss per share (vs JP¥1.39 loss in FY 2023) Jun 28
Forecast breakeven date pushed back to 2026 Jun 24 See more updates
CYBERDYNE Inc. Announces on the New Product Medical Vital Sensor Cyvis M100 Dec 10
CYBERDYNE Inc. to Report First Half, 2025 Results on Nov 14, 2024 Sep 20
First quarter 2025 earnings released: EPS: JP¥0.052 (vs JP¥1.56 in 1Q 2024) Aug 19
Now 21% overvalued after recent price rise Jul 12
Full year 2024 earnings released: JP¥6.99 loss per share (vs JP¥1.39 loss in FY 2023) Jun 28
Forecast breakeven date pushed back to 2026 Jun 24
CYBERDYNE Inc. to Report Q1, 2025 Results on Aug 14, 2024 Jun 06
New minor risk - Share price stability Jun 05
Full year 2024 earnings released: JP¥6.99 loss per share (vs JP¥1.39 loss in FY 2023) May 20 U.S. FDA Becomes the world's First to Clear Smaller Model of Medical HAL and Expanded Indication for Cerebral Palsy
U.S. FDA Becomes the world's First to Clear Smaller Model of Medical HAL and Expanded Indication for Cerebral Palsy May 16
CYBERDYNE Inc. to Report Fiscal Year 2024 Results on May 15, 2024 Mar 09
Third quarter 2024 earnings released: JP¥1.65 loss per share (vs JP¥0.93 loss in 3Q 2023) Feb 16
New minor risk - Share price stability Jan 18
CYBERDYNE Inc. to Report Q3, 2024 Results on Feb 14, 2024 Dec 27
Forecast breakeven date pushed back to 2026 Dec 15
Second quarter 2024 earnings released: JP¥4.42 loss per share (vs JP¥0.13 profit in 2Q 2023) Nov 19 Nov 17
CYBERDYNE Inc. to Report Q2, 2024 Results on Nov 14, 2023 Oct 05
CYBERDYNE Inc. to Report First Half, 2024 Results on Nov 14, 2023 Sep 16
First quarter 2024 earnings released: EPS: JP¥1.56 (vs JP¥1.12 in 1Q 2023) Aug 15
CYBERDYNE Inc. to Report Q1, 2024 Results on Aug 14, 2023 Jul 07
New minor risk - Share price stability Jul 05
Forecast breakeven date pushed back to 2025 May 31
Full year 2023 earnings released: JP¥1.39 loss per share (vs JP¥2.29 loss in FY 2022) May 18
Forecast breakeven date pushed back to 2026 May 18
CYBERDYNE Inc., Annual General Meeting, Jun 22, 2023 May 16
CYBERDYNE Inc. to Report Fiscal Year 2023 Results on May 15, 2023 Feb 18
Third quarter 2023 earnings released: JP¥0.93 loss per share (vs JP¥0.74 loss in 3Q 2022) Feb 16
CYBERDYNE Inc. to Report Q3, 2023 Results on Feb 14, 2023 Jan 07
Cyberdyne Inc. Announces Yuzo Toda Passed Away on December 27, 2022, and Retired from the Position of Director on the Same Day Jan 06
Less than half of directors are independent Nov 16
CYBERDYNE Inc. to Report First Half, 2023 Results on Nov 14, 2022 Aug 16
First quarter 2023 earnings released: EPS: JP¥1.13 (vs JP¥1.28 loss in 1Q 2022) Aug 14
CYBERDYNE Inc. to Report Q1, 2023 Results on Aug 12, 2022 May 17
Full year 2022 earnings released: JP¥2.29 loss per share (vs JP¥0.27 loss in FY 2021) May 16
Forecast breakeven date pushed back to 2025 May 14
CYBERDYNE Inc., Annual General Meeting, Jun 30, 2022 May 14
Less than half of directors are independent Apr 27
Now 23% undervalued after recent price drop Mar 07
Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat Feb 16
CYBERDYNE Inc. to Report Fiscal Year 2022 Results on May 13, 2022 Feb 16
Forecast breakeven date pushed back to 2023 Feb 15
Second quarter 2022 earnings released: JP¥0.70 loss per share (vs JP¥1.38 profit in 2Q 2021) Nov 15
Forecast to breakeven in 2022 Sep 23
CYBERDYNE Inc. Announces Medical HAL Single Joint Type Receives Medical Device Approval from Australian Therapeutic Goods Administration, Department of Health Sep 03
CYBERDYNE Inc. (TSE:7779) acquired C2,Inc. Sep 01
First quarter 2022 earnings released: JP¥1.28 loss per share (vs JP¥0.60 loss in 1Q 2021) Aug 18
Cyberdyne Inc. Preliminary Results of Medical Hal Lower Limb Type Stroke Clinical Trial Jun 24
Forecast breakeven moved forward to 2022 May 17
Full year 2021 earnings released: JP¥0.27 loss per share (vs JP¥0.71 loss in FY 2020) May 17
New 90-day low: €4.96 Mar 02 CYBERDYNE Inc., Annual General Meeting, Jun 24, 2021
CYBERDYNE Inc Forms Strategic Partnership with Cellsource Co., Ltd Feb 16
Third quarter 2021 earnings released: JP¥0.40 loss per share (vs JP¥0.46 profit in 3Q 2020) Feb 15
Revenue misses expectations Feb 15
New 90-day low: €5.00 Jan 20
CYBERDYNE Inc. to Report Q3, 2021 Results on Feb 12, 2021 Jan 07
CYBERDYNE Inc. Medical Hal Obtains Approval from Singapore Health Science Authority Dec 20
CYBERDYNE Inc. Announces that Stroke Clinical Trial on Medical HAL is Complete Dec 13
Cyberdyne Inc. Exports Six Units of Its Wearable Cyborg Hal (Three Units of Lower Limb Type, Two Units of Single Joint Type, One Unit of Lumbar Type) to Institute of Brain & Spine Hospital Nov 19
New 90-day high: €6.75 Nov 17
Second quarter 2021 earnings released: EPS JP¥1.38 Nov 15
Revenue beats expectations Nov 15
CYBERDYNE Inc. Obtains a Medical Device Approval for HAL for Medical Use Lower Limb Type Oct 18
Malaysian Public Social Security Organization Expands Cybernics Treatment to 4 Major Sites in Malaysia Oct 17
CYBERDYNE Inc. to Report Q2, 2021 Results on Nov 13, 2020 Oct 10
New 90-day high: €5.25 Oct 07
CYBERDYNE Inc. Announces Marketing Clearance From U.S. FDA for Medical HAL Expands To Stroke And Progressive Neuromuscular Disease Oct 06
New 90-day high - €4.00 Sep 10
First quarter earnings released Aug 16
New 90-day low - €3.28 Jul 27
CYBERDYNE Inc. to Report Q1, 2021 Results on Aug 14, 2020 Jun 28 Shareholder Returns 8C4 DE Medical Equipment DE Market 7D -8.4% -2.9% -2.6% 1Y -28.1% -8.5% 6.9%
See full shareholder returns
Return vs Market: 8C4 underperformed the German Market which returned 6.9% over the past year.
Price Volatility Is 8C4's price volatile compared to industry and market? 8C4 volatility 8C4 Average Weekly Movement 6.5% Medical Equipment Industry Average Movement 6.6% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 8C4 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 8C4's weekly volatility (6%) has been stable over the past year.
About the Company CYBERDYNE Inc. researches, develops, produces, sell, leases, and maintains robotic equipment and systems for medical and welfare in Japan, the United States, Europe, the Middle East, Africa, and the Asia Pacific countries. The company offers Hybrid Assistive Limb (HAL) for medical use in lower limb and single joint type; non-medical HAL for lower limb, single joint type, and lumbar type; HAL peripherals; cleaning robots; transportation robots for various transportation tasks in factories, offices, and other indoor environments; Acoustic X, a high-speed light pulse LED array light source that enables real time photoacoustic imaging; and CYIN for living support, which is an interface that uses biological information that can be controlled voluntarily outside of muscle activities. It also provides Cybernics Treatment, a treatment that uses HAL to enhance and regenerate the function of the wearer for spinal cord injury, stroke, neuromuscular diseases, etc.; Neuro HALFIT for enhancement of brain-nerve-musculoskeltal system; MTX Neuro HAL Plus to enhance the performance of the athletes’ brain-nerve functions; and Neuro HALFIT at home for enhancement of physical functions.
Show more CYBERDYNE Inc. Fundamentals Summary How do CYBERDYNE's earnings and revenue compare to its market cap? 8C4 fundamental statistics Market cap €204.47m Earnings (TTM ) -€7.22m Revenue (TTM ) €26.93m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 8C4 income statement (TTM ) Revenue JP¥4.39b Cost of Revenue JP¥2.08b Gross Profit JP¥2.31b Other Expenses JP¥3.49b Earnings -JP¥1.18b
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -5.58 Gross Margin 52.58% Net Profit Margin -26.82% Debt/Equity Ratio 0.3%
How did 8C4 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 03:32 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2024/03/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources CYBERDYNE Inc. is covered by 10 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution null null Astris Advisory Japan, K.K. Hidemaru Yamaguchi Citigroup Inc Takahiro Mori Daiwa Securities Co. Ltd.
Show 7 more analysts 
